

BioSquare 2009: Panels & Workshops

BioSquare Sessions: Monday, March 9, 2009

	Panels and Workshops	Parallel One-to-one meetings
10:45 am/ 12:00pm	Workshop 1 -Comparison between the public financial supports of Biotech	
10:45 am/ 12:00pm	Workshop 2 - New Antibiotherapies for tomorrow	
10:45 am/ 12:00pm	Workshop 3 - The Cleantech Market in Europe	
1:00 pm/ 2:15 pm	Opening Plenary Session	
2:15 pm / 3:30 pm	Panel 1 - More R&D investment but no more drugs approved. What's wrong?	Yes
4:00 pm / 5:30 pm	Panel 2 - The Brain Device Interface	Yes
5:30 pm / 6:30 pm	Workshop 4 - New trends in nanomedicine	Yes
5:30 pm / 6:30 pm	Workshop 5 -Theranostics	Yes
5:30 pm / 6:30 pm	Workshop 6 - Cellular Therapies, challenging but promising	Yes

Panels and Workshops:

With renowned experts and professionals from the industry, academia, and regulatory bodies, sharing their views and experience, the BioSquare conference analyzes new industry trends and developments and discusses the approaches biotechnology companies can adopt in facing the current challenges. Topics cover partnering, finance and other issues of importance to the biotech industry.



Interactive Workshops: You will be provided with practical tools for problem solving. We specifically limit the number of participants and encourage audience participation.

Panel Discussions: Comprehensive discussion on topics of interest to the entire audience.

Opening Plenary Session

Monday, March 9, 1:00 p.m. to 2:15 pm **Venue: Auditorium Pasteur**, Lyon Convention Centre, France

Session presentation:

The challenge for biotechnology: providing innovative solutions to a wide range of Health, Agri /Food and Environmental issues in the next five years to come.



Confirmed speakers:

- **Gilles Bloch**, Director General of Research and Innovation, Ministry of Higher Education and Research
- **Steen Riisgaard**, Chairman for EuropaBio
- **Dr Tim Hall**, Acting Director: Biotechnologies, Agriculture and Food, DG Research, European Commission
- **Elias A. Zerhouni**, Former Director, U.S. National Institutes of Health
- **Marc Cluzel** - Senior Vice President Research and Development , Sanofi

Moderator: Maria Cattai, former Secretary of the International Chamber of Commerce and Managing Director of the World Economic Forum (Davos)

PANEL N°1 – More R&D investment but no more drugs approved. What's Wrong?

Monday, March 9, 2.15 pm to 15.30 pm, **Venue: "Auditorium Pasteur"**, Lyon Convention Center, France

Session presentation:

There seems to be a bad omen on drug development. Despite the vertiginous rise of "R&D" budgets it looks like fewer treatments are reaching the market. Recent examples of newly approved therapies only to be withdrawn at the first adverse effect even darken the picture. The speakers of this first panel will thus question the actual paradigm of drug discovery and development. Is there too many opportunities for a successful assessment as may feel many Start-up Executives of Venture Capitals looking for take-over? Are we validating with the wrong tools? Are we fighting against an unreachable regulatory "glass roof"? Are there places outside Europe and the US where relevant and easier Phase II validation could be obtained?

Confirmed speakers:

- **Richard Seebrook**, Head of Business Development Technology Transfert, Welcome Trust
- **Ludo Lauwers**, Sr. Vice President, Vice Chairman Management Board Janssen Pharmaceutica NV
- **Daniel Cohen**, CEO, Pharnext

Moderator: Philippe Pouletty, Chairman of France Biotech, Founder and General Partner of Truffle Capital

PANEL N°2 – The Brain Device Interface

Monday, March 9, 4 pm to 5.30 pm, **Venue: "Auditorium Pasteur"** Lyon Convention Centre, France

Session presentation:

Recent successful experiments have shown the public that building a real brain-machine-Interface was not rocket-science. If a monkey can let a robot walk on the opposite side of the earth, when will a paraplegic just stand-up and walk. The participants to this panel will present both on the discovery/innovation side but also on the business

opportunity side the most recent development in this new area, also prompting that the interface between the brain and a device of interest does not necessarily imply contact or energy transfer.

Confirmed speakers:

- **Alim Louis Benabid**, Professor Emeritus at "Joseph Fourier" University, Grenoble, France
- **Fernand Badano**, Chief Operating Officer, Valtronic Technologies, France
- **Jonas Garding**, Doctor Of Research and Physics, Elekta, Sweden
- **Philippe E. Laurent**, M.D, PhD, Vice President – Medical Affairs for Becton Dickinson Medical Pharmaceutical Systems
- **Dr. Andrew Schwartz**, a professor of neurobiology at the University of Pittsburgh

WORKSHOP N°1 – Comparison between the public financial supports of Biotech

Monday, March 9, 10.45 am to 12.00 am, **Venue:** "Saint Clair 1" hall, Lyon Convention Center, France

Session presentation:

Developing innovative therapies is not only a business adventure but also a societal crusade. Therefore have most of the developed country established public policies meant to financially support the high risk phases of new treatment discovery, design and validation. The participants to this first Workshop will not only draw a landscape of the public financing inside and outside Europe but also try to answer the question of the efficacy of these policies with respect to the always raising complexity of the regulatory barrier.

Confirmed speakers:

- **Willy De Greef**, Secretary General of EuropaBio
- **Yves Laurent**, General Manager, Lyonbiopôle
- **Marie-Laure Muiras**, Project Director, ACIES
- **Daniel Vasmant**, Head of the Health, Biotechnology and Food Industry department, General Directorate for Competitiveness, Enterprise and Services of the French ministry of the French Ministry of Economy, Industry and employment
- **Alex Gordon**, Liaison Office Director, Technion

Moderator: **Line Matthiessen**, Head of Unit, Research Directorate, European Commission, **TBC**

WORKSHOP N°2 – New Antibiotherapies for tomorrow

Monday, March 9, 10.45 am to 12.00 am, **Venue:** "Saint Clair 2" hall, Lyon Convention Center, France

Session presentation:

Antibiotic strategies are probably the most ancient medicine as proved by recent discoveries on the sophisticated NO activating based protection of the "eye gate" by Egyptian kohl. Nevertheless, or maybe because our war against microbe is not new, the XXIst century needs more than ever new antibiotics to fight against new resistances of well known pathogens and the rise of new ones. In parallel there is a real danger of dry-up as conventional ways to design and assess antibiotics seems less and less efficient. During the WORKSHOP N°2 the most advanced and successful approaches as well as the characteristics of future opportunities will be exposed.

Confirmed speakers:

- **Jeff Hillman**, Chief Scientific Office, ONI BioPharma, Inc
- **Peter Hamman**, Sanofi
- **Alice Dautry**, General Director, Institut Pasteur, **TBC**

Moderator: Tim Joslin, Defined Health's Managing Director, Europe

WORKSHOP N°3 – The Cleantech Market in Europe

Monday, March 9, 10.45 am to 12.00 am, **Venue:** "Saint Clair 3 A" hall, Lyon Convention Center, France

Session presentation:

What have the Cleantechs to do with the Biotechs? This question is much less academic than it may appear at first glance. The speakers of the Workshop N°3 will debate along two different lines of relation between those two Markets. Do Cleantechs and Biotech compete, or even maybe cannibalize each-other, for funding? How is triggered this competition? What are the latent synergies between these two markets, set on the same technological roots and tools? How can the Biotech Entrepreneur take the best out of these synergies?

Confirmed speakers:

- **François Houssin**, Senior Development Manager, European Listing, NYSE Euronext, France
- **Peter Rosholm**, Vice President Biopharma area - Novozymes

WORKSHOP N°4 – New trends in nanomedicine

Monday, March 9, 5.30 pm to 6.30 pm, **Venue:** "Saint Clair 1" hall, Lyon Convention Centre, France

Session presentation:

Alongside the dramatic regulatory maze that face conventional drug development the Medical Device market look like a highway to innovative therapies. Nevertheless new development, particularly when based on the miniaturization of the devices (for instance the uses of nano-particles), or new matter-wave interactions (ultrasound for therapy) raise new questions as well as new opportunities. What are the forecasted evolutions of the regulatory frame to cope with these new solutions? Do we have all the needed tool for straightforward validations of the efficacy and risk assessment? Regulatory expert, Academics and Entrepreneurs will debate on these issues during WORKSHOP N°4.

Confirmed speakers:

- **Laurent Lévy**, CEO - Nanobiotics
- **Jean Chabbal**,CEA: head of the technologies for healthcare division

WORKSHOP N°5 – Theranostics

Monday, March 9, 5.30 pm to 6.30 pm, **Venue:** "Saint Clair 2" hall, Lyon Convention Center, France

Session presentation:

The word Theranostics may be unknown to you even if you are an actor of the biotech industry. It means combining in one single operation, therapy with highly specific diagnostics. It thus covers a large span of potential applications and more interestingly new business opportunities. From individual profiling to fine tune the immunomodulator dosing following organ transplantation to the use of specific antigens for combined cancer treatment and visualization of attack against the targeted tumor, Theranostic seems to enable endless combinations. To identify the most up-to-date opportunities the participants to the WORKSHOP N°5 will be given access to the recent developments on this new market that is also strongly connected with recent sociological and regulatory evolutions.

Confirmed speakers:

- **Prof. Ariel Miller**
- **Marc Essodaigui**, Vice President Marketing & Sales, Europe & Asia - Ipsogen

- **Alain Huriez**, CEO - TC Land
- **Michael Lutz**, PGx Health/Epidauros
- **Allan Barge**, Vice President Oncology, AstraZeneca, **TBC**

WORKSHOP N°6 – Cellular Therapies, challenging but promising

Monday, March 9, 5.30 pm to 6.30 pm, **Venue:** "Saint Clair 3 A" hall, Lyon Convention Center, France

Session presentation:

We will probably never cure cancer by trying to transfect all mutated cells with a bioengineered vector. But working on somatic or tumorous stem cells, we might very well be able to grow new organs, produce large quantity of bio-active molecules, implant fully bio-compatible medical devices for the long-lasting delivery of endogenous biomolecules, or rebuild deficient immunological or neural systems. This new approaches have also raised philosophical concerns among Europe and the United States raising a high barrier for the development of these therapies. We will discuss these issues and present the challenges and the main opportunities in that field alongside the first clinical validations.

Confirmed speakers:

- **Michael Siani-Rose**, President and Founder of Theregen, Inc.